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An understanding of the mutations of the proto-oncogenes and tumor suppressor genes that occur in thyroid cancers should
eventually explain the diverse clinical characteristics of these tumors and also direct therapy. Some insights have already emerged
in the last decade; some abnormalities in tumor genes are consistently associated with speciﬁc clinical and pathologic ﬁndings.
These genetic abnormalities usually represent somatic mutations in tumors of follicular epithelial origin, as opposed to inherited
mutations in medullary thyroid cancers of parafollicular C cells origin because most thyroid tumors are sporadic and not familial.
Thisisdiﬀerentfromthemultipleendocrineneoplasiasyndromesinwhichtheprimarytumorigenicgenemutationsareinherited.
This improved understanding of the molecular basis of these diseases has led to the development of novel targeted therapeutic
approaches which will be discussed in this paper.
1.Introduction
Thyroid cancer is the most common form of malignant
endocrine tumor. In 2002, the estimated incidence of thyroid
cancer worldwide was reported to be in excess of 141000 [1]
with a female predilection (more than 75% being women).
The thyroid gland is composed of two main parenchymal
cell types. Diﬀerentiated thyroid cancers arise from follicular
cells giving rise to 3 separate subgroups, papillary, follicular,
and hurtle cell. The 3 diﬀerent subtypes have diﬀerent
clinical behavior. Papillary thyroid cancer (PTC) forming
80% of all thyroid cancers has a 10-year survival rate of more
than 90%. PTC displays a spectrum of diﬀerentiation from
well diﬀerentiated, tall cell variant, to poorly diﬀerentiated.
Follicular thyroid cancer (FTC) constitutes 10% of all
thyroid cancers with a wider range of 10-year survival
between 43%–94% indicating great heterogeneity within the
same disease entity [2–4]. Hurthle cell carcinoma is the
most infrequent diﬀerentiated carcinoma arising from the
follicular cells with incidence estimated to be between 3%–
10%. The overall survival rates for Hurthle cell carcinoma
are similar or worse compared to follicular carcinoma. One
study showed disease-free survival of 40.5% at 10 years
[5].
Anaplastic thyroid cancers (ATCs) are undiﬀerentiated
tumors of the thyroid follicular epithelium. In marked
contrast to diﬀerentiated thyroid cancers, anaplastic cancers
are extremely aggressive, with a disease-speciﬁc mortality
approaching 100%. Fortunately, anaplastic thyroid cancer
accounts for only 2%–5% of all thyroid cancers [2–4, 6].
Medullary thyroid carcinoma (MTC) is a neuroendocrine
tumor which arises from parafollicular or C cells of the
thyroid gland. MTC accounts for 3%–5% of all thyroid
cancers and portends a higher mortality rate [2, 3].
The prognosis of thyroid cancer as a whole is generally
favourable representing only 0.5% (35000) of all cancer
deaths [7]. However, prognosis for patients with metastatic,
iodine nonavid, diﬀerentiated thyroid cancer and anaplastic
cancer remains poor. This paper reviews the therapeu-
tic options available for this subset of patients. Better
understanding of molecular pathogenesis of thyroid cancer
coupled with signiﬁcant advances made in cancer therapy
guarantees promising and exciting therapeutic options in
years to come.2 Journal of Oncology
2. DifferentiatedThyroid Cancer (DTC)
Papillary and follicular thyroid cancers are often treated
similarly albeit numerous biologic diﬀerences. Standard
of care of diﬀerentiated thyroid cancer consists of total
thyroidectomy often followed by radioactive iodine (RAI)
when indicated, aiming for remnant ablation and adjuvant
therapy. High-risk patients (age >45, male gender, presence
of metastatic disease, extra-thyroidal tumour extension, and
tumour diameter >4cm) should also receive thyroid stim-
ulating hormone (TSH) suppression therapy with thyroid
hormone[8].Upto25%–50%ofpatient’stumorlosesability
to take up iodine. This is attributed to downregulation of
sodium iodide (NaI) symproter (NIS). Promoter methyla-
tion of genes required for NaI metabolism leads to decreased
expression and is linked to increased signaling through the
MAPK pathway [9].
Overall survival (OS) rapidly falls once thyroid cancer
metastasize, and is no longer amenable to radioiodine
therapy making chemotherapy the only option for systemic
treatment. Doxorubicin has been recognized as the standard
of care since 1970s based on response rate of 30% in
a population of 30 patients [10] .T h i sp e r h a p si sa n
overestimate of the eﬃcacy of doxorubicin as subsequent
trials did not achieve similar response rates. A phase two
trial evaluating the eﬃcacy of doxorubicin combined with
cisplatin yielded a response rate of less than 10%. The
progression-free survival (PFS) time of the patients was
estimated at 2 months, and median overall survival was 8
months [11]. Clearly, novel strategies are needed in view
of limitations of conventional cytotoxic therapy. Increasing
knowledge on cancer thyroid biology has provided an
impetus to identifying novel therapeutics and rational trial
designs.
Thyroid cancers are highly vascular and express high
levels of vascular endothelial growth factor (VEGF) [12].
Inhibition of VEGF receptor signaling alone or in combi-
nation has been shown to inhibit growth of thyroid tumors
in orthotopic nude mouse [13]. VEGFR therefore seems an
attractive and plausible target in iodine refractory metastatic
thyroid cancer in humans.
PTC frequently carries gene mutations and rearrange-
ments that lead to activation of the mitogen activated pro-
tein kinase (MAPK). Rearrangements of RET and NTRK1
tyrosine kinases, activating mutations of BRAF and RAS are
sequentialcomponentsleadingtoactivationofMAPK.These
gene alterations are mutually exclusive given any PTC [14,
15]. PTC is associated with rearrangements of two diﬀerent
transmembrane tyrosine kinase genes: RET and NTRK1.
These rearrangements result in the production of chimeric
proteins with tyrosine kinase activity that contributes to
the development of the malignant phenotype. The chimeric
genes resulting from RET rearrangements are referred to as
RET/PTC and those resulting from NTRK1 rearrangements
as TRK. Of note, TRK is an extremely rare occurrence.
On average, no more than 20% of PTCs have such rear-
rangements with at least 6 diﬀerent chimeric RET/PTC and
TRK genes shown. TRK may be associated with a more
aggressive clinical behavior [16] whilst RET/PTC possibly
has a more favorable prognosis [17].The RAF proteins are
serine-threonine kinases that activate the RAF/MEK/MAPK
signaling pathway. The T1799A mutation of the BRAF
gene, occurs in 29%–69% of papillary thyroid cancers
[14, 18–20]. The predicted protein product BRAFV600E
in PTC is associated with reduced expression of key genes
governing iodine metabolism, speciﬁcally the impairment of
both NIS expression and targeting to membrane leading to
dediﬀerentiation [21, 22]. BRAF mutations have also been
shown to be associated with extrathyroidal invasion, lymph
node metastasis, and advanced tumor stage hence conferring
a worse clinical prognosis compared to BRAF wild-type [23].
Finally, Ras has also been reported in follicular variant of
PTC in which no clear evidence of aggressiveness has been
found [24]. It is worthy to note that the genetic changes
linked with pathogenesis of PTC are mutually exclusive.
The translocation t(2;3)(q13;p25) has been identiﬁed in
FTC which results in fusion of part of the DNA-binding
segment of the PAX8 gene and the peroxisome proliferator-
activated receptor gamma 1 (PPAR-gamma-1) gene; PAX8
is a thyroid transcription factor, and PPAR-gamma-1 is a
transcription factor that stimulates cell diﬀerentiation and
inhibits cell growth. The product of the fusion gene blocks
the action of the PPAR-gamma-1, an eﬀect that might
inhibit cell diﬀerentiation and stimulate cell growth [25].
Overexpression of normal c-myc and c-fos genes, as well as
mutations of H-ras, N-ras, and K-ras proto-oncogenes, is
found in follicular cancers. These abnormalities may confer
a growth-promoting eﬀect that may act additively with other
oncogene or tumor suppressor gene mutations [26, 27].
The above discovery over the last 5–10 years allowed
clinical trials of new therapies for well-diﬀerentiated thyroid
cancer.
Motesanib diphosphate is an oral tyrosine kinase
inhibitor (TKI) targeting the VEGFR 1-3, PDGFR, and cKIT.
A multicentre, open-label phase 2 trial was initiated testing
the eﬃcacy of this drug in a cohort of 93 patients with
progressive DTC. Of the 93 patients, 30% were still on drug
after 48 weeks. The partial response (PR) rate was 14% with
another 35% maintaining stable disease for at least 24 weeks.
The median progression-free interval was 40 weeks. The
mostcommonsideeﬀectsincludedfatigue,nausea,diarrhea,
hypertension, and unexpectedly increased requirements in
thyroxine replacement [28].
Axitinib is another oral TKI that blocks VEGFR, PDGFR
and cKIT. A multicentre phase II trial examined the eﬃcacy
of axitinib in advanced or metastatic thyroid carcinoma of
which 75% had DTC. There was 31% PR rate among the
DTC patients. Median PFS was 18 months. Common side
eﬀects were all typical of this class of drug [29].
Sorafenib is an oral TKI targeting VEGFR 2 and 3, RET
and BRAF, cKIT, PDGFR, and FLt-3. Two phase II trials were
performed in patients with metastatic PTC. Kloos et al. [30]
investigatedtheuseofsorafenibamong36evaluablepatients,
and PR was seen in 8%, with a minor response (deﬁned
as 23%–29% reduction in tumor diameter) in another
19%. Gupta-Abramson et al. [31] showed that out of 30
patients with metastatic iodine refractory thyroid carcinoma
who received sorafenib 400m twice a day, 23% had a PRJournal of Oncology 3
lasting up to 84 weeks and 53% achieving stable disease
(SD). The median PFS was 79 weeks. In the latest update
in abstract form [32], out of 50 evaluable patients, 36%
achieved PR and 46% SD with clinical beneﬁt rate of 82%.
PFS measured was 84 weeks. The median OS of the initial
cohortof30patientswas140weeks.Thiscomparesfavorably
with the historic OS of patients treated with doxorubicin.
Patients who harbor BRAFV600E mutation which was a
poor prognostic marker in the prekinase era trended towards
better outcome when treated with sorafenib compared with
patients with wild-type BRAF. Sorafenib is now recognized
as a potential therapeutic agent in the NCCN guidelines and
is FDA approved for treatment of advanced hepatocellular
carcinoma and advanced renal cell carcinoma.
Sunitinib an oral small molecule TKI which demon-
strates VEGFRs, RET, and RET/PTC subtypes 1 and 3 inhi-
bition was tested in 31 patients. 13% of the patients achieved
PR whilst 68% had documented disease stabilization [33].
Severe adverse eﬀects were similar to that of sorafenib. In
another phase II trial where sunitinib was administered on a
continuous basis at 37.5mg every day to 33 patients (26 had
well-diﬀerentiated thyroid carcinoma), complete response
was seen in 2 patients (7%), 25% had PR, and 48% had
SD with a clinical beneﬁt rate of 83% [34]. Thus, sunitinib
is also available for use in selected thyroid cancer patients
with metastatic disease outside of clinical trial. Despite early
promise of geﬁtinib demonstrating eﬃcacy in preclinical
models on the premise of many papillary thyroid cancers
displaying activated EGF receptor signaling, the phase II
study was met with disappointing results. There was no
documented objective response with median progression of
only 4 months [35].
Two phase 2 studies have just been reported in ASCO
2010 in refractory thyroid carcinoma. AZD6244, an oral
inhibitor of mitogen-activated protein kinase, MEK-1/2, was
found to result in median progression-free of 32 weeks
[36]. Aﬂibercept, a VEGF-trap, was evaluated in 21 patients
culminating in stable disease rate of 83% [37].
In a phase II trial, 29 patients with metastatic diﬀer-
entiated thyroid cancer were treated with increasing doses
of thalidomide. PR was reported in about 20 percent of
patients, SD was seen in about 35 percent, and there were
no complete responses. Most common and serious toxicities
included fatigue, infection, and neuropathy, and half of
patientsdiscontinuedtherapyduetosideeﬀects[38].Twenty
one patients were treated with 25mg on lenalidomide in
an open label phase two trial with PR of 22% and SD
44%. Treatment was well tolerated with mainly grade 3
hematological toxicities [39].
There are clearly multiple agents which have been tested
at phase II levels which have tremendous results warranting
validation in phase 3 clinical trials. Future trials should
perhaps investigate eﬃcacy of combination targeted therapy
with chemotherapy in ﬁrst line treatment of advanced
thyroid cancer. There are currently a few phase I/II trials
underway investigating other targets such as BRAFV600E
selective kinase inhibitor, proteaosome inhibitor, and PPAR-
gamma agonist. Everolimus, an mTOR inhibitor, has shown
preclinical activity and warrants further testing [40].
3. AnaplasticThyroid Carcinoma (ATC)
ATC is uncommon and comprises 1%-2% of thyroid malig-
nancies. ATC typically aﬀects elderly patients with median
age of 68 at diagnosis. It has a fulminant course with
almost 100% disease-speciﬁc mortality. The median survival
is approximately 4 months with one year overall survival of
16%–19% [41].
ATC may originate de novo or from preexisting PTC
or FTC. A number of gene mutations have been identiﬁed.
Mutation of the p53 tumor suppressor gene has been
identiﬁed in up to 70% of anaplastic thyroid cancers [42].
Production of inactive p53 protein leads to dysregulation
of both apoptosis and the cell cycle. Mutations within the
β-catenin gene occur in up to 65% of ATC [43]. The
beta catenin protein plays a role in cell adhesion and in
signaling through the Wnt pathway. The exon 3 mutation
is associated with increased nuclear localization of the beta
catenin resulting in increased nuclear signaling and hence
tumorigenesis or tumor progression.
It seems likely that in some PTC, dediﬀerentiation may
lead to ATC. This is highlighted by studies showing between
15%–50% of ATC containing BRAF mutation [44, 45].
Interestingly, the incidence of BRAF mutation has been
reportedtobeashighas62%inradioactiveiodine-refractory
thyroid cancers [46] .M u t a t i o n si n v o l v i n gR A S( r e g u l a t e s
the RAS-RAF-MEK-ERK and PI3K/AKT1 pathways) are
found to aﬀect between 6%–50% of ATC [47, 48]. Somatic
mutationsofthecatalyticsubunitofthephosphatidylinositol
3 -kinase (PIK3CA) have been identiﬁed in about 23 percent
of anaplastic thyroid cancers [49].
Clinical management of anaplastic thyroid cancer hinges
onretrospectiveseriesofmajorcentresowingtoitsrarityand
thus lack of randomized studies.
For ATC localized to the thyroid, complete resection
should be attempted in conjunction with postoperative
adjuvant therapy. At Roswell Cancer Institute, the 5-year
overall survival of the patients who achieved complete
resection was 60% [50]. In contrast, Kobayashi et al. [51]
r e p o r t e da1 - y e a rs u r v i v a lr a t eo f2 0 %f o rp a t i e n t sw h o
had complete resection whilst no one with residual disease
was alive. Haigh et al. [52] managed 33 patients and found
surgical resection with curative intent in eight which resulted
in median survival of 43 months and 5-year survival of 50%.
Most received adjuvant chemoradiotherapy. Meanwhile, De
Crevoisier[53]reportedhighlong-termsurvivalwhenradio-
chemotherapy was administered after complete resection.
These patients received 6 cycles of doxorubicin (60m/m2)
and cisplatin (120ng/m2) with 40Gy of external beam
radiotherapy(EBRT).Attheendoftreatment,completelocal
response was seen in 19 patients. With a median followup
of 45 months, 7 patients were still in complete remission of
which 6 had previously achieved complete resection. All the
above together with SEER analysis lends support to adjuvant
radio/chemotherapy in improving survival outcomes. How-
ever this is confounded by the fact that patients who received
adjuvant treatment usually have less extensive disease.
There is no eﬀective therapy for advanced or metastatic
anaplastic thyroid cancer, and the disease is uniformly fatal.4 Journal of Oncology
The median survival from diagnosis ranges from three to
seven months, and the one-year survival rate ranges 20%–
35% [50, 52].
ECOG conducted a prospective trial from 1976 to 1982
whereby 21 patients were randomized to doxorubicin versus
18 randomized to doxorubicin plus cisplatin. The single
agentarmhadonepartialresponsewhilethe2-drugregimen
produced 3 complete responses and 3 partial responses.
Median survival however was only 2.7 months. There were
however 2 prolonged CRs lasting 35 and 41 months [54].
Ain et al. conducted a phase II clinical trial exploring eﬃcacy
of paclitaxel as a 96-hour infusion. The objective response
rate was 52%. Overall survival was 6 months with a higher
median survival of 32 weeks in the 10 responders [55].
Like its diﬀerentiated counterpart, understanding of the
molecularpathogenesishasallowedstudiesonnoveltargeted
agents to be carried out. Combretastatin A-4 phosphate
(CA4P), a tubulin binding disrupting agent, showed some
interesting ﬁndings in the study of Dowlati et al. [56]. One
of the 3 patients with ATC achieved complete response
and was alive at 30 months. However, in a later phase II
trial, out of 18 patients, no objective responses were seen; 6
had stable disease, and 12 patients progressed with median
survivalof20weeks.ItappearsthatCA4Phaslimitedeﬃcacy
as a single agent, and perhaps combination with either
chemotherapy or another targeted agent may be beneﬁcial
[57]. Combination of high-dose intermittent geﬁtinib was
evaluatedinaphaseItrial,andonepatientwithATChada4-
month partial remission [58]. Cohen et al. evaluated axitinib
in phase II trial. Two patients with ATC were enrolled. One
had a PR of 4 months whilst the other patients progressed
[29].
Several agents are currently being tested in phase I or
II settings for advanced anaplastic thyroid cancer including
CS7017, an oral PPAR inhibitor, in combination with
paclitaxel, imatinib and bavituximab in combination with
doxorubicin and pemetrexed with paclitaxel.
4.MedullaryThyroid Carcinoma(MTC)
Medullary thyroid cancers (MTCs) are tumors of thyroid
parafollicular C cells which are part of the amine precursor
uptake decarboxylation (APUD) system rather than thyroid
epithelial cells. MTCs do not concentrate iodine. They may
occur as sporadic tumors, as a component of multiple
endocrine neoplasia type (MEN) 2, or as a familial MTC
syndrome without MEN association. The gender distribu-
tion is equal. The tumor is unilateral in majority of sporadic
forms but mostly bilateral and multifocal in familial cases.
They secrete calcitonin and sometimes carcinoembryonic
antigen (CEA), both of which can serve as tumor markers
[59]. Calcitonin production is stimulated by both calcium
andpentagastrin.Thisformsthebasisofthestimulationtests
using calcium infusion [60, 61]. The primary treatment for
MTC is extensive and meticulous surgical resection. Total
thyroidectomy is frequently needed in addition to complete
resection of lymph nodes in the central neck, paratracheal
and upper mediastinal region. Fortunately, mutations in the
RET proto-oncogene have now been established in MEN-2.
Family members can be screened at birth, obviating yearly
provocative testing and allowing aﬀected members to be
oﬀered early thyroidectomy [62].
Among patients with recurrent local or distant disease,
the rate of progression is variable, and some patients survive
for years despite obvious metastatic disease. This fact also
makes assessment of the eﬃcacy of any therapy very diﬃcult;
about all that can be done is to determine whether a therapy
leads to tumor shrinkage. Despite these limitations, it seems
clear that external beam radiotherapy is rarely eﬀective, and
chemotherapy has only occasionally been eﬀective.
The treatment of MTC using cytotoxic drugs has mir-
rored the historical development of chemotherapy use in
neuroendocrine tumors. Single agent regimens have been
characterized by low response rates (<10%) and/or lack of
durable response. Doxorubicin, aclarubicin, mitoxantrone,
and streptozocin were the agents investigated previously as
monotherapy [63–65]. Dacarbazine in combination with
other drugs is recommended for patients with metastatic
MTCinguidelinesfromtheNationalComprehensiveCancer
Network [66]. Dacarbazine plus 5-ﬂuorouracil (5-FU) is
an active combination. In one series, three of ﬁve patients
had a partial response, while in a second study, one patient
had a complete remission lasting ten months. In preclinical
studies, the novel tubulin-binding agent combretastatin A-4
phosphate, in combination with doxorubicin, was active in a
xenograft model of MTC in nude mice. Preclinical evidence
from the same centre also suggested activity for irinotecan in
MTC cell lines [67].
Other modalities evaluated including interferon alpha,
long-acting somatostatin analog, yttrium-90-labelled
somatostatin analogs, and immunotherapy have largely
found to confer marginal clinical beneﬁt [68–74].
A marine cyclodepsipeptide, aplidin (plitidepsin),
extracted from a Mediterranean tunicate was investigated in
a phase I trial involving six patients with MTC out of 67 with
thyroid cancers. Four of the six had stable disease for over six
months [75]. Since many MTC patients have spontaneous
disease stabilization, this is not deﬁnitive results; however
this drug merits further investigation. A small molecule
inhibitor, arylidene-2-indolinone (RPI-1), abolishes the
constitutive tyrosine phosphorylation caused by the speciﬁc
RET proto-oncogene mutation seen at cysteine residue
634 in the syndrome multiple endocrine neoplasia type 2A
(MEN2A). Hopefully, this agent will have future applications
both in inherited MTC as well as in papillary cancers
associated with the RET/PTC1 gene rearrangement [76].
Another novel therapeutic approach includes modula-
tion of angiogenesis considering that VEGF is elevated in
75% of metastatic MTC [77]. Several phase 2 studies have
been conducted to evaluate the eﬃcacy of this strategy. 91
patients with advanced/metastatic medullary thyroid cancer
were treated with motesanib diphosphate in a multicentre
trial. Although the objective response rate was only 2%,
almost half of the patients experienced prolonged stable
disease [78]. Similarly, sunitinib was noted to confer an
overall response rate of 35% and clinical beneﬁt rate of
91% in another study involving 25 patients [79]. BuildingJournal of Oncology 5
on the knowledge that germline or somatic mutations of
RET account for 75% of MTC, a randomized, double-blind
phase 3 trial involving 331 patients was conducted utilizing
vandetanib an oral inhibitor of RET, VEGFR, and EGFR.
Although the overall survival analysis is immature it is
assuring to note that patients treated with vandetanib had
a signiﬁcantly longer progression-free survival compared to
the placebo group (HR 0.45, P = .0001) [80]. Antitumor
activity has been noted in XL184, an oral inhibitor of RET,
MET, and VEGFR2. Hepatocyte growth factor (FGF) recep-
tor tyrosine kinase (MET) has also been detected in MTC
andtransductionofnormalhumanthyroidcellswithmutant
RET results in upregulation of MET. Moreover preclinical
model suggests that MET and VEGFR2 play synergistic roles
in promoting tumor angiogenesis and dissemination [81].
A phase 1 dose ﬁnding study involving 37 patients with
MTC yielded PR rate of 29% and prolonged SD of 68%
[82]. The eﬃcacy of XL 184 is currently being evaluated in
a randomized phase 3 trial.
5. Conclusion
The improved understanding of the molecular basis of
pathogenesis and development of thyroid cancers of fol-
licular epithelial origin and medullary thyroid cancers has
vastly increased the armamentarium of therapeutic options
available to the patient with metastatic disease. A continued
rational approach to the development of these therapeutic
modalities will further deﬁne their future clinical applica-
tions.
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